© P o l s k i e T o w a r z y s t w o G i n e k o l o g i c z n e Nr 2/2014
158
+MRIOSP4SP
7XERS[MWOS>IWTSÜY)OWTIVX´[4SPWOMIKS8S[EV^]WX[E
+MRIOSPSKMG^RIKSHSX]G^ÂGIWXSWS[ERMETVITEVEX´[
^E[MIVENÂG]GLQ]SMRS^]XSPTV^I^TEGNIRXOM^^IWTSÜIQ
TSPMG]WX]G^R]GLNENRMO´[ 4'37
>IWT´ÜIOWTIVX´[TSPWOMIKS8S[EV^]WX[E+MRIOSPSKMG^RIKS
[WOÜEH^MI
4VSJHVLEF4V^IQ]WÜE[3W^YOS[WOM
-RWX]XYX'IRXVYQ>HVS[ME1EXOM4SPOM[ÛSH^M Prof. dr hab. Artur Jakimiuk
Instytut Matki i Dziecka w Warszawie 4VSJHVLEF1EVIO7TEG^]ÞWOM
9RM[IVW]XIX1IH]G^R][4S^RERMY Prof. dr hab. Jacek Szamatowicz
9RM[IVW]XIX1IH]G^R]&MEÜ]QWXSOY 4VSJHVLEF%KEXE/EVS[MG^&MPMÞWOE
9RM[IVW]XIX1IH]G^R][ÛSH^M 4VSJHVLEF)[E2S[EO1EVO[MX^
9RM[IVW]XIX1IH]G^R][4S^RERMY
4VSJHVLEF0IGLSWÜE[4YXS[WOM 9RM[IVW]XIX1IH]G^R][0YFPMRMI (VRQIH8EHIYW^-WEEX
Instytut Matki i Dziecka w Warszawie
RETSWMIH^IRMY[HRMYWX]G^RMEVSOYW^G^IK´ÜS[S
TV^IEREPM^S[EÜ HSWXÊTRÂ PMXIVEXYVÊ REYOS[Â HSX]G^ÂGÂ WXSWS
[ERMEQ]SMRS^]XSPY[TV^]TEHOYTEGNIRXIO^^IWTSÜIQTSPMG]
WX]G^R]GLNENRMO´[
(SHEXOS[STV^IEREPM^S[ERS[RMOPM[MIMRJSVQEGNÊSTVSHYO
GMI-RSJSPMGpHSWXEVG^SRÂTV^I^TVSHYGIRXETVSHYOXYPIG^RMG^IKS
7XERS[MWOSTV^IHWXE[MEWXER[MIH^]RE[]õIN[]QMIRMS
R]XIQEXREH^MIÞTV^ITVS[EH^IRMEEREPM^]>IWT´ÜIOWTIVX´[
^EWXV^IKEWSFMITVE[SHSEOXYEPM^EGNMRMRMINW^IKSWXERS[MWOE
[ TV^]TEHOY TSNE[MIRME WMÊ RS[]GL MWXSXR]GL HSRMIWMIÞ RE
ukowych.
>IWT´Ü TSPMG]WX]G^R]GL NENRMO´[ 4'37 HSX]G^] SH OSFMIXMNIWXNIHRÂ^RENG^ÊWXW^]GLTV^]G^]R^EFYV^IÞQMIWMÂG^
OS[ERMESVE^RMITÜSHRSêGMOSFMIGINEXEOõIVS^[SNYXEOMGL^E
FYV^IÞNEO REHGMêRMIRMIXÊXRMG^IH]WPMTMHIQMEGYOV^]GEX]TY--
SVE^GLSVSF]WIVGS[SREG^]RMS[I>QRMINW^SRE[VEõPM[SêÄXOE
RIOREMRWYPMRÊTVS[EH^ÂGEHSLMTIVMRWYPMRIQMMWXERS[MTSHWXE
[S[ÂTV^]G^]RÊVS^[SNYSFVE^YOPMRMG^RIKS4'37?A
3TSVRSêÄMRWYPMRS[E[]WXÊTYNIY OSFMIXSX]Ü]GLSVE^
Y OSFMIXW^G^YTÜ]GL[TV^IFMIKY4'37
Stanowisko Zespołu Ekspertów Polskiego Towarzystwa Ginekologicznego dotyczące stosowania preparatów zawierających myo-inozytol, przez pacjentki z zespołem policystycznych jajników (PCOS)
Statement of the Polish Gynecological Society on the application
of myo-inozytol in patients with PCOS (Polycystic Ovary Syndrome)
© P o l s k i e T o w a r z y s t w o G i n e k o l o g i c z n e
Nr 2/2014
159
7 8 % 2 3 ; - 7 / 3 > ) 7 4 3 Û 9 ) / 7 4 ) 6 8 ; +MRIOSP4SP
Stanowisko Zespołu Ekspertów PTG dotyczące stosowania preparatów zawierających myo-inozytol, przez pacjentki z zespołem policystycznych jajników (PCOS).
,MTIVMRWYPMRIQME WX]QYPYNI TVSHYOGNÊ ERHVSKIR´[ [ OS
Q´VOEGL XIOEPR]GL NENRMOE TSTV^I^ VIGITXSV MRWYPMRS[] SVE^
VIGITXSVHPEMRWYPMRSTSHSFRIKSG^]RRMOE[^VSWXYTVS[EH^MHS
[^QSõSRIN TVSHYOGNM ERHVSKIR´[ [ NENRMOEGL SVE^ HS TV^IH
[G^IWRINEXVI^NMTÊGLIV^]O´[FVEOYS[YPEGNMM^QRMINW^IRMETVS
HYOGNMKPSFYPMR][MÂõÂGINWXIV]H]TÜGMS[I 7,&+
4EXSQIGLERM^Q MRWYPMRSSTSVRSêGM [ 4'37 RMI ^SWXEÜ HS
OSÞGE TS^RER] ?A 4SHOVIêPE WMÊ VSPÊ MRS^]XSPSJSWJSKPMOER´[
-4+ NEOSQIHMEXSV´[[I[RÂXV^OSQ´VOS[IKSH^MEÜERMEMRWYPM
R]MTV^IOE^YW]KREÜY[I[RÂXV^OSQ´VOS[IKS?A
-RS^]XSPREPIõ]HSKVYT][MXEQMR&^HMIXÂHSWXEVG^ERINIWX
SO K MRS^]XSPY KÜ´[RMI [ JSVQMI Q]SMRS^]XSPY 1=3 1=3
[]HENI WMÊ SHKV][EÄ OPYG^S[Â VSPÊ [ OW^XEÜXS[ERMY QSVJSKI
RI^] M G]XSKIRI^] OSQ´VIO W]RXI^] XÜYW^G^´[ X[SV^IRMY FÜSR
OSQ´VOS[]GLM[TVE[MHÜS[]Q[^VSêGMIOSQ´VOM.IWXSRXEOõI
TVIOYVWSVIQJSWJSPMTMH´[OX´VIWÂSHTS[MIH^MEPRI^EKIRIVS[E
RMI[EõR]GL[I[RÂXV^OSQ´VOS[]GLW]KREÜ´[[SFVÊFMISSG]XY
?A3HKV][E[EõRÂVSPÊ[TVSGIWMITVE[MHÜS[IKSHSNV^I[ERME
SSG]X´[^EV´[RS[SFVÊFMIG]XSTPE^Q]NEOMNÂHVEOSQ´VOS[I
KSENIKS^QRMINW^SRIWXÊõIRMI[SFVÊFMITÜ]RYTÊGLIV^]OS[I
KSOSVIPYNI^KSVW^ÂNEOSêGMÂOSQ´VIONENS[]GL?A
*SWJSKPMOER]^E[MIVENÂGIMRS^]XSPSOVIêPERIWÂNEOSHVYKMI
TV^IOEóRMOMW]KREÜYMRWYPMRS[IKS[I[RÂXV^OSQ´VOM>MHIRX]JM
OS[ERSH[EKÜ´[RITV^IOEóRMOM[^EPIõRSêGMSHVSH^ENYWXIVIS
M^SQIVY[GLSH^ÂGIKS[NIKSWOÜEH 1=3-4+SVE^GLMVSMRS^]XSP
('--4+
1=3-4+ NEOS TV^IOEóRMO W]KREÜY [I[RÂXV^OSQ´VOS[I
KSQEW[´NYH^MEÜKÜ´[RMI[TVSGIWMI[]GL[]XYKPYOS^]TV^I^
OSQ´VOÊSVE^[TV^IOE^][ERMYW]KREÜ´[^EPIõR]GLSH*7,? A
>EFYV^IRMI TV^IOE^][ERME W]KREÜY HSOSQ´VOS[IKS TV^I^ VI
GITXSVMRWYPMRS[]TS[SHYNI^QRMINW^IRMIXVERWTSVXYHSOSQ´V
OS[IKS-4+M^QRMINW^IRMINIKSWXÊõIRME[OSQ´VGI? A4SQM
QSSF[SHS[INMRWYPMRSSTSVRSêGMXOERIO[SFVÊFMINENRMOERMI
WX[MIVH^EWMÊ^QRMINW^SRIN[VEõPM[SêGMREMRWYPMRÊ,MTIVMRWYPM
RIQMETVS[EH^MHS^[MÊOW^SRINTVSHYOGNMERHVSKIR´[[OSQ´V
OEGLXIOEPR]GLNENRMOESVE^HS^[MÊOW^SRIKSY[EPRMERME-27
?A>[MÊOW^SREITMQIV]^EGNE1=3HS('-SVE^XVERWTSVXHSOS
Q´VOS[] ('--4+ TVS[EH^M HS ^EFYV^SRIN TVSTSVGNM 1=3-4+
HS ('--4+ TS[SHYNÂG HEPW^I ^[MÊOW^IRMI WX]QYPEGNM OSQ´VIO
XIOEPR]GLHSTVSHYOGNMERHVSKIR´[[WT´PRMI^W]KREÜIQTSGLS
H^ÂG]QFI^TSêVIHRMS^VIGITXSVEMRWYPMRS[IKS?A
>I[^KPÊHYRETSX[MIVH^SRI[]WXÊTS[ERMILMTIVMRWYPMRIQMM
YOSFMIX^4'37WYFWXERGNIY[VEõPM[MENÂGIXOEROMREH^MEÜERMI
MRWYPMR]QENÂ^EWXSWS[ERMI[PIG^IRMY^IWTSÜYSH[MIPYPEX0IOM
XEOMINEOQIXJSVQMRETMSKPMXE^SRXVSKPMXE^SR^QRMINW^ENÂLMTI
VMRWYPMRIQMÊ SVE^ LMTIVERHVSKIRIQMÊ E X]Q WEQ]Q TS[SHYNÂ
TS[V´XVIKYPEVR]GLG]OPMQMIWMÂG^OS[]GLSVE^S[YPEGNMYOSFMIX
^4'37?A
>QRMINW^SRE HSWXÊTRSêÄ OSQ´VOS[E PYF ^QMIRMSR] QIXE
FSPM^Q MRS^]XSPY PYF -4+ MGL RMIHSF´V ^EFYV^SRI WXÊõIRME PYF
TVSTSVGNISHKV][ENÂMWXSXRÂVSPÊ[VS^[SNYLMTIVMRWYPMRIQMMTVS
[EH^ÂGHSSFVE^YOPMRMG^RIKS4'37
>QRMINW^IRMILMTIVMRWYPMRIQMM[[]RMOYWYTPIQIRXEGNM1=3
PYF('-TVS[EH^MHS^[MÊOW^IRMEG^ÊWXSXPM[SêGMS[YPEGNMTV^]
[V´GIRMEVIKYPEVRSêGMQMIWMÂG^OS[ERME^QRMINW^IRMELMTIVER
HVSKIRM^QYSVE^TSTVE[]KSWTSHEVOM[ÊKPS[SHERS[IN
; KVYTMI TV^]NQYNÂGIN 1=3 ^EY[EõSRS MWXSXRI WXEX]WX]G^
RMI ^QRMINW^IRMI WXÊõIRME 0, M TVSPEOX]R] SVE^ WXSWYROY 0,
*7,>ESFWIV[S[ERSXEOõITSTVE[ÊTEVEQIXV´[SGIRMENÂG]GL
MRWYPMRSSTSVRSêÄ [WOEóRMOE ,31% WXÊõIRME MRWYPMR] [ XIêGMI
SFGMÂõIRMEKPYOS^ÂSVE^[WOEóRMOE[VEõPM[SêGMREMRWYPMRÊ -7-
3FWIV[S[ERS TV^][V´GIRMI VIKYPEVRIKS V]XQY OV[E[MIÞ QMI
WMÊG^R]GL M ^QRMINW^IRMI SFNÊXSêGM NENRMO´[ G^ÊWXW^I []WXÊTS
[ERMI S[YPEGNM []õW^I WXÊõIRME TVSKIWXIVSRY [ JE^MI
PYXIEPRIN E XEOõI ^QRMINW^IRMI WXÊõIRME [SPRIKS XIWXSWXIVSRY
^[MÂ^ERI^I^[MÊOW^SR]QWXÊõIRMIQ 7,&+ SVE^^REG^ÂG]WTE
HIOWXÊõIRMEHIL]HVSITMERHVSWXIVSRY[IOV[M?A
2E TSHWXE[MI HSWXÊTRIN PMXIVEXYV] QSõRE WX[MIVH^MÄ Mõ
WXSWS[ERMI TVITEVEX´[ MRS^]XSPY QE [TÜ][ RE TV^][V´GIRMI
TVE[MHÜS[INS[YPEGNMYTEGNIRXIO^4'374V´F]WXSWS[ERMEKS
YOSFMIX[]OE^YNÂG]GLSTSVRSêÄRETSHWXE[S[]PIOMRHYOYNÂG]
S[YPEGNÊ Ā OPSQMJIR []QEKENÂ HEPW^]GL FEHEÞ VERHSQM^S[E
R]GL?A
4SPIG^IRMYSX]Ü]GLTEGNIRXIO^^IWTSÜIQ4'3TSTSHERMY
1=3WX[MIVH^SRSSFRMõIRMI[WOEóRMOEQEW]GMEÜEMMRWYPMRSSTSV
RSêGMWXÊõIRMEMRWYPMR]0,SVE^WXSWYROY0,*7,M[WOEóRMOE
,31%-Q[]õW^EMRWYPMRSSTSVRSêÄYSX]Ü]GLOSFMIXX]QPITW^E
F]ÜEWOYXIG^RSêÄXIVETMMLMTIVMRWYPMRIQMMMYWXÊTS[ERMISFVE^Y
OPMRMG^RIKS 4'37 ; [MÊOW^SêGM TV^]TEHO´[ HSW^ÜS XEOõI HS
TV^][V´GIRME VIKYPEVRIKS QMIWMÂG^OS[ERME 2MI WX[MIVH^SRS
VIHYOGNM&1-YTEGNIRXIOTV^]NQYNÂG]GLQ]SMRS^]XSP? A
4SV´[RYNÂGH[MIKVYT]TEGNIRXIO^4'37^OX´V]GLNIHRE
TV^]NQS[EÜEX]POSERX]OSRGITGNÊHSYWXRÂEHVYKEERX]OSRGIT
GNÊ ^ 1=3 [ KVYTMI ^ 1=3 WX[MIVH^SRS MWXSXRI ^QRMINW^IRMI
LMVWYX]^QY[WOEPM*IVVMQERE+EPP[E]ăEWTEHIOWXÊõIRMEERHVS
KIR´[[WYVS[MG]OV[M^QRMINW^IRMILMTIVMRWYPMRIQMMQMIV^SRI
WXSWYROMIQKPYOS^]HSMRWYPMR]M[WOEóRMOMIQ,31%SVE^^ESF
WIV[S[ERSTSTVE[ÊKSWTSHEVOMPMTMHS[IN?A
9TEGNIRXIO^4'37TV^IHM[XVEOGMITVSXSOSÜ´[OSRXVSPS
[ERIN LMTIVWX]QYPEGNM NENIG^OS[ERME WX[MIVH^SRS Mõ TEGNIRXOM
TV^]NQYNÂGI 1=3 []QEKEÜ] QRMINW^IN GEÜOS[MXIN HE[OM KS
REHSXVSTMR SVE^ QMEÜ] RMõW^I WXÊõIRME IWXVEHMSPY [ WYVS[MG]
OV[M[HRMY^EOSÞG^IRMEWX]QYPEGNM2MõW^]V´[RMIõF]ÜSHWIXIO
RMIHSNV^EÜ]GLSSG]X´[[TSV´[RERMY^KVYTÂTV^]NQYNÂGÂX]POS
O[EWJSPMS[]GLSGMEõSHWIXIOGMÂõRMIV´õRMÜWMÊ^REQMIRRMITS
QMÊH^]KVYTEQM?A
; KVYTMI TEGNIRXIO ^ 4'37 TV^IH -:* TV^]NQYNÂG]GL 1=3
M('-[TSV´[RERMY^KVYTÂWXSWYNÂGÂX]POS('-[]OE^ERSXEOõI
TSTVE[Ê NEOSêGM SSG]X´[ IQFVMSR´[ SVE^ ^[MÊOW^SR] SHWIXIO
GMÂõTSXVERWJIV^I
6´[RMIõYTEGNIRXIOFI^^IWTSÜY4'3TV^]NQYNÂG]GL1=3
PYFMRS^]XSP[]OE^ERSTSTVE[ÊNEOSêGMSSG]X´[SVE^^QRMINW^I
RMIHE[IOKSREHSXVSTMR[XVEOGMIWX]QYPEGNMNENIG^OS[ERME?A
4V^IHWXE[MSRI FEHERME []OE^YNÂ OSV^]WXRI H^MEÜERMI TS
GLSHR]GLMRS^]XSPYYTEGNIRXIO^4'37
-RSJSPMGpNIWXSFIGRMINIH]R]QTVITEVEXIQREV]ROY^E[MI
VENÂG]QQ]SMRS^]XSP.IWXSRWYTPIQIRXIQHMIX]TSHTSWXEGMÂ
TVSW^OYHSWTSV^ÂH^ERMEVS^X[SVYM^E[MIVENÂG]QKMRS^]XSPY
SVE^þKO[EWYJSPMS[IKS[WEW^IXGI
)OWTIVGM48+WXSNÂREWXERS[MWOYMõOSV^]WXRINIWXWXSWS[E
RMITVITEVEXY-RSJSPMGpYTEGNIRXIO^4'37[HE[GI\WEW^IX
OE H^MIRRMI GIPIQ TV^][V´GIRME TEVEQIXV´[ QIXEFSPMG^R]GL
IRHSOV]RSPSKMG^R]GLMTV^][V´GIRMEVIKYPEVRSêGMS[YPEGNM(S
HEXOS[SHE[OS[ERMIXEOMITS^[EPERETSOV]GMIHSFS[INWYTPI
QIRXEGNMO[EWIQJSPMS[]QYOSFMIXTPERYNÂG]GLGMÂõÊ
;]HENIWMÊF]ÄXEOõI^EWEHRIWXSWS[ERMITVITEVEXY-RSJS
PMGp [ TV^]TEHOY TEGNIRXIO ^ 4'37 TSHHE[ER]GL TVSGIHYV^I
© P o l s k i e T o w a r z y s t w o G i n e k o l o g i c z n e Nr 2/2014
160
7 8 % 2 3 ; - 7 / 3 > ) 7 4 3 Û 9 ) / 7 4 ) 6 8 ; +MRIOSP4SP
Stanowisko Zespołu Ekspertów PTG dotyczące stosowania preparatów zawierających myo-inozytol, przez pacjentki z zespołem policystycznych jajników (PCOS).
OSRXVSPS[ERINLMTIVWX]QYPEGNMNENRMO´[TV^IHTVSGIHYVEQM%68
^I[^KPÊHYRETSTVE[ÊNEOSêGMSSG]XYSVE^^QRMINW^IRMIHE[IO
PIO´[WXSWS[ER]GL[XVEOGMIWX]QYPEGNM9TEGNIRXIO^4'37PI
G^SR]GLERX]OSRGITGNÂLSVQSREPRÂVIOSQIRHS[ERENIWXXEOõI
WYTPIQIRXEGNETVITEVEXIQ-RSJSPMGp^I[^KPÊHYRENIKSMWXSXR]
[TÜ][REKSWTSHEVOÊPMTMHS[Â[ÊKPS[SHERS[ÂMLSVQSREPRÂ
-RSJSPMGp NIWX WYFWXERGNÂ FI^TMIG^RÂ ; õEHRIN ^ HSX]GL
G^EWSTYFPMOS[ER]GLTVEGFEHE[G^]GLRMIWX[MIVH^ERSH^MEÜEÞ
YFSG^R]GL1=3ETV^]NQS[ERMITVITEVEXYGLEVEOXIV]^S[EÜSWMÊ
HYõÂEOGITXEGNÂ^IWXVSR]TEGNIRXIOSMPIRMITV^IOVEG^ERS^EPI
GER]GLHE[IO?A
>IWT´Ü IOWTIVX´[ OMIVYNÂG WMÊ )&1 )ZMHIRGI &EWIH
1IHMGMRI HÂõ]HS^ETI[RMIRMERMI^EPIõRSêGMMSFMIOX][M^QY
[I[W^]WXOMGLW[SMGLH^MEÜERMEGLIHYOEG]NR]GL
%YXSV^] TS[]õW^IKS STVEGS[ERME RMI ^KÜSWMPM OSRJPMOXY
MRXIVIW´[^[MÂ^ERIKS^XÂTYFPMOEGNÂ
Piśmiennictwo
1. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.Hum Reprod. 2010;25:544.
2. Goodarzi MO, Jones MR, Chen YD, Azziz R. First evidence of genetic association between AKT2 and polycystic ovary syndrome. Diabetes Care. 2008 ;31:2284-7
3. Amin M, Abdel-Kareem O, Takekida S, Moriyama T, Abd el-Aal G, Maruo T. Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. Kobe J Med Sci. 2003;49:59-73
4. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012 ;28:509-15.
5. Jakimiuk A, Szamatowicz J. Rola niedoboru inozytolu w patofizjologii zaburzeń występujących w zespole policystycznych jajników. Ginekol Pol, 2014, 85, 54-57.
6. Akiba S, Sato T. Cellular function of calcium-independent phospholipase A2. Biol Pharm Bull.
2004;27:1174-8
7. Lisi F, Carfagna P, Oliva MM et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol 2012, 10, 52
8. Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288:1405-11
9. Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome. Metab Syndr Relat Disord. 2010;8:127-36
10. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012 ;16:575-81.
11. Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (m/c) ratios and increased m/c epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls Endocr J. 2013 2.
12. Rouzi AA, Ardawi MS. A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate- resistant polycystic ovary syndrome. Fertil Steril. 2006;85:428-35.
13. Larner J, Brautigan DL, Thorner MO. D-chiro-inositol glycans in insulin signaling and insulin resistance. Mol Med. 2010;16:543-52.
14. Genazzani AD, Lanzoni C, Ricchieri F et al. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008,24,139-144
15. Constatino D, Minozzi G, Ninozii E et al. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009,13,105-110
16. Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, Marelli G, Cino I, Redaelli A, Ferrari A. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol. 2007 ;23:700-3
17. Raffone E, Rizzo P, Benedetto V. Insulin sensitizer agents alone and in co-treatment with rFSH for ovulation induction in PCOS women. Gynecol Endocrinol 2010,26,275-80
18. D’Anna R, Di Benedetto V, Rizzo P, Raffone E, Interdonato ML, Corrado F, Di Benedetto A. Myo- inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol. 2012;28:440-2 19. Gennazani AD, Prati A, Santagni S et al. Diferential insulin response to myo-onositol
administration on obese polycystic ovary syndrome patients. Gynecol Endocrinol 2012, 27,1473-77
20. Artini A, Berardino F, Papini F et al. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecol Endocrinol 2013, 29, 375-9 21. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis
and treatment of polycystic ovary syndrome: an endocrine society clinical practice guideline J Clin Endocrinol Metab. 2013;98:4565-92
22. Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo- inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome Gynecol Endocrinol.
2011;27:920-4.
23. Brusco GF, Mariani M. Inositol: effects on oocyte quality in patients undergoing ICSI. An open study. Eur Rev Med Pharmacol Sci. 2013 ;17:3095-102
24. Carlomagno G, Unfer V. Inositol safety: clinical evidences Eur Rev Med Pharmacol Sci. 2011
;15:931-6
